Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

An Examination of the Association between FOXA1 Staining Level and Biochemical Recurrence following Salvage Radiation Therapy for Recurrent Prostate Cancer.

Heckman MG, Robinson JL, Tzou KS, Parker AS, Wu KJ, Hilton TW, Howat WJ, Miller JL, Kreinest PA, Pisansky TM, Schild SE, Peterson JL, Vallow LA, Carroll JS, Buskirk SJ.

PLoS One. 2016 Mar 17;11(3):e0151785. doi: 10.1371/journal.pone.0151785. eCollection 2016.

2.

GATA2 expression and biochemical recurrence following salvage radiation therapy for relapsing prostate cancer.

Robinson JL, Tzou KS, Parker AS, Heckman MG, Wu KJ, Hilton TW, Pisansky TM, Schild SE, Peterson JL, Vallow LA, Buskirk SJ.

Br J Radiol. 2017 Jul;90(1075):20170174. doi: 10.1259/bjr.20170174. Epub 2017 Jun 16.

3.

Evaluation of MDM2, p16, and p53 staining levels as biomarkers of biochemical recurrence following salvage radiation therapy for recurrent prostate cancer.

Heckman MG, Parker AS, Wu KJ, Hilton TW, Ko SJ, Pisansky TM, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ.

Prostate. 2012 Dec 1;72(16):1757-66. doi: 10.1002/pros.22528. Epub 2012 Apr 18.

PMID:
22513981
4.

Outcomes of extremely low risk prostate cancer following radical prostatectomy.

Lee EW, Laze J, Lepor H.

Prostate Cancer Prostatic Dis. 2011 Sep;14(3):266-9. doi: 10.1038/pcan.2011.21. Epub 2011 May 3.

PMID:
21537347
5.

Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.

Cortés-González JR, Castellanos E, Sandberg K, Eriksson MH, Wiklund P, Carlsson S, Cohn-Cedermark G, Harmenberg U, Gustafsson O, Levitt SH, Lennernäs B, Brandberg Y, Márquez M, Kälkner KM, Nilsson S.

Int J Oncol. 2013 Jan;42(1):109-17. doi: 10.3892/ijo.2012.1694. Epub 2012 Nov 13.

PMID:
23151842
6.

Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy.

Lee RJ, Tzou KS, Heckman MG, Hobbs CJ, Rawal B, Diehl NN, Peterson JL, Paryani NN, Ko SJ, Daugherty LC, Vallow LA, Wong W, Schild S, Pisansky TM, Buskirk SJ.

BJU Int. 2016 Aug;118(2):236-42. doi: 10.1111/bju.13229. Epub 2015 Aug 22.

7.

Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.

Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T.

Eur Urol. 2014 Sep;66(3):479-86. doi: 10.1016/j.eururo.2013.11.045. Epub 2013 Dec 12.

PMID:
24345725
8.

Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy.

Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY.

Cancer. 2013 Sep 15;119(18):3287-94. doi: 10.1002/cncr.28215. Epub 2013 Jul 2.

9.

Lack of Association between COX-2 Staining Level and Biochemical Recurrence Following Salvage Radiation Therapy for Recurrent Prostate Cancer.

Heckman MG, Tzou KS, Parker AS, Pisansky TM, Schild SE, Hilton TW, Patel VN, Pelaez L, Khor LY, Peterson JL, Daugherty LC, Vallow LA, Pollack A, Buskirk SJ.

J Radiat Oncol. 2013 Sep 1;2(3):309-314.

10.

Factors influencing biochemical recurrence in patients who have received salvage radiotherapy after radical prostatectomy: a systematic review and meta-analysis.

Jia ZW, Chang K, Dai B, Kong YY, Wang Y, Qu YY, Zhu YP, Ye DW.

Asian J Androl. 2017 Jul-Aug;19(4):493-499. doi: 10.4103/1008-682X.179531. Review.

11.

Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.

Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng FY.

Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):275-81. doi: 10.1016/j.ijrobp.2013.05.043. Epub 2013 Jul 23.

PMID:
23886418
12.

Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence.

Malik RD, Goldberg JD, Hochman T, Lepor H.

Eur Urol. 2011 Sep;60(3):548-53. doi: 10.1016/j.eururo.2011.05.036. Epub 2011 May 26.

PMID:
21652145
13.

Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?

MacDonald OK, Schild SE, Vora S, Andrews PE, Ferrigni RG, Novicki DE, Swanson SK, Wong WW.

Urology. 2004 Oct;64(4):760-4.

PMID:
15491716
14.

Salvage radiation therapy following radical prostatectomy. A national Danish study.

Ervandian M, Høyer M, Petersen SE, Sengeløv L, Hansen S, Holmberg M, Sveistrup J, Meidahl Petersen P, Borre M.

Acta Oncol. 2016 May;55(5):598-603. doi: 10.3109/0284186X.2015.1088170. Epub 2015 Sep 23.

PMID:
26399602
15.

Five-year biochemical recurrence-free and overall survival following high-dose-rate brachytherapy with additional external beam or radical prostatectomy in patients with clinically localized prostate cancer.

Boehm K, Schiffmann J, Tian Z, Lesmana H, Larcher A, Mandel P, Karakiewicz PI, Graefen M, Schwarz R, Krüll A, Tilki D.

Urol Oncol. 2016 Mar;34(3):119.e11-8. doi: 10.1016/j.urolonc.2015.09.012. Epub 2015 Oct 23.

PMID:
26602027
16.

Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.

Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall'Oglio M, Srougi M, Scardino PT, Eastham JA.

Eur Urol. 2011 Aug;60(2):205-10. doi: 10.1016/j.eururo.2011.03.011. Epub 2011 Mar 21.

17.

HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.

Asimakopoulos AD, Miano R, Virgili G, Vespasiani G, Finazzi Agrò E.

Urol Oncol. 2012 Sep;30(5):577-83. doi: 10.1016/j.urolonc.2010.08.019. Epub 2011 Feb 2.

PMID:
21292508
18.

(68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.

van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L.

BJU Int. 2016 May;117(5):732-9. doi: 10.1111/bju.13397. Epub 2016 Jan 24.

19.

Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.

Goenka A, Magsanoc JM, Pei X, Schechter M, Kollmeier M, Cox B, Scardino PT, Eastham JA, Zelefsky MJ.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):112-8. doi: 10.1016/j.ijrobp.2011.10.077. Epub 2012 Jan 31.

PMID:
22300563
20.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

Supplemental Content

Support Center